KRYS Krystal Biotech, Inc.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: commercializing gene therapies targeting rare monogenic diseases, led by approved topical VYJUVEK for dystrophic epidermolysis bullosa (DEB)
• • New emphasis on diverse clinical pipeline including KB407 (cystic fibrosis), KB408 (AAT deficiency), ophthalmic KB803 & KB801, dermatology KB111, oncology KB707, and aesthetics via Jeune Aesthetics
• • Strategic broadened focus from dermatology to respiratory, ophthalmology, oncology, and aesthetic segments, with ongoing regulatory and reimbursement expansions in Europe and Japan
• • VYJUVEK net product revenue $389.1M in 2025, gross margin 94%; quarterly launches in Germany, France, Japan plus pipeline clinical progress in Phase 1-3 for multiple candidates
• • Noteworthy: FDA granted platform technology designation to HSV-1 vector for KB801 in October 2025, underscoring innovation in ocular gene therapy delivery

Risk Factors

• • Regulatory risk from Biologics Price Competition and Innovation Act (BPCIA) allowing biosimilar competition after 12 years exclusivity on VYJUVEK
• • Geopolitical risk from uncertain regulatory approval of VYJUVEK outside U.S., EU, Japan limiting international revenue
• • Operational risk in scaling manufacturing process for VYJUVEK, subject to risks and uncertainties with demand fluctuations
• • Competitive risk from companies developing advanced gene therapies or biosimilars, potentially rendering VYJUVEK obsolete
• • Financial risk of IRA drug pricing reforms including Medicare price negotiations, inflation rebates, and new $2,000 out-of-pocket cap effective 2025

Management Discussion & Analysis

• • No revenue or profitability data disclosed in the provided MD&A excerpt
• • No segment performance or cash flow details included
• • No capital allocation details such as buybacks, dividends, or capex provided
• • No management outlook, guidance, or emerging risks described in text provided

What are the latest KRYS SEC filings in 2026?

Krystal Biotech, Inc. (KRYS) has filed a 10-K annual report on February 17, 2026, a 10-Q quarterly report on May 4, 2026, an 8-K current report on August 3, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did KRYS file its most recent 10-K annual report?

Krystal Biotech, Inc. (KRYS) filed its most recent 10-K annual report on February 17, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view KRYS 10-Q quarterly reports?

Krystal Biotech, Inc. (KRYS)'s most recent 10-Q quarterly report was filed on May 4, 2026. SignalX displays every KRYS 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has KRYS filed recently?

Krystal Biotech, Inc. (KRYS)'s most recent 8-K was filed on August 3, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find KRYS insider trading activity (Form 4)?

SignalX aggregates every KRYS Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does KRYS file with the SEC?

Krystal Biotech, Inc. (KRYS) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new KRYS filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Krystal Biotech, Inc. (KRYS).

What is KRYS's SEC CIK number?

Krystal Biotech, Inc. (KRYS)'s SEC CIK (Central Index Key) number is 1711279. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1711279 to look up all KRYS filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find KRYS return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Krystal Biotech, Inc. (KRYS) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.